Commentary: Lessons from the Analysis of Non-human Primates for Understanding Human Aging and Neurodegenerative Diseases by Andre Menache & Anne Beuter
February 2016 | Volume 10 | Article 331
General Commentary
published: 02 February 2016
doi: 10.3389/fnhum.2016.00033
Frontiers in Human Neuroscience | www.frontiersin.org
Edited by: 
Agustin Ibanez, 
Universidad Diego Portales, Chile
Reviewed by: 
Arjan Blokland, 
Maastricht University, Netherlands 
Carlos Barcia, 
Universitat Autònoma de Barcelona, 
Spain
*Correspondence:
Andre Menache  
andre.menache@gmail.com
Received: 08 October 2015
Accepted: 19 January 2016
Published: 02 February 2016
Citation: 
Menache A and Beuter A (2016) 
Commentary: Lessons from the 
Analysis of Non-human Primates for 
Understanding Human Aging and 
Neurodegenerative Diseases. 
Front. Hum. Neurosci. 10:33. 
doi: 10.3389/fnhum.2016.00033
Commentary: lessons from the 
analysis of non-human Primates for 
Understanding Human aging and 
neurodegenerative Diseases
Andre Menache1* and Anne Beuter2
1 Antidote Europe, Perpignan, France, 2 Bordeaux Polytechnic Institute, Bordeaux, France
Keywords: non-human primate, Parkinson’s disease, animal model, prediction, neuromodulation
A commentary on
Lessons from the analysis of nonhuman primates for understanding human aging and 
neurodegenerative diseases
by Verdier J, Acquatella I, Lautier C, Devau G, Trouche S, Lasbleiz C, et al. Front Neurosci (2015) 9:64. 
doi:10.3389/fnins.2015.00064
We agree with Verdier et al. (2015) that the use of animals may be scientifically viable in some areas 
of research, but we feel that the animal model is not sufficiently evidence-based to be considered 
as a valid predictive modality for the study of human disease. Our view is supported by empirical 
evidence (the lack of predictive ability of preclinical animal tests in the field of regulatory toxicol-
ogy), by complexity theory (the inability of one evolved complex system to predict the response of 
a different evolved complex system to a given substance or stimulus) and by evolutionary biology 
(humans and other mammals share many of the same genes, but gene regulation can vary widely 
between different mammalian species) (Shanks and Greek, 2009; Godlee, 2014).
Therefore, we view as somewhat contradictory some of the arguments presented in relation to the 
following concluding remark proposed by the authors: “NHPs should only be used when no other 
suitable method is available to fill the gap of our knowledge” (page 4). For example, in the section enti-
tled “The MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine) NHP models of neurodegeneration 
and the renaissance of Parkinson’s disease (PD) research,” the authors write: “Importantly, the MPTP 
NHP models allowed the identification of the neural circuits affected in Parkinson’s disease, specifi-
cally the role of excessive activity in the subthalamic nuclei (Bergman et al., 1990), leading to the 
development of ablative procedures (Baron et al., 2002) and of deep-brain stimulation (DBS) of these 
nuclei (DeLong and Benabid, 2014). These latter experiments (sic) would not have been developed 
without knowing the physiology of the basal ganglia in non-human primates (Baron et al., 2002).”
The MPTP primate model of PD proposed by Burns et al. (1983) followed the observation of 
a case of parkinsonism occurring after the self-administration by a 23-year-old man of an illicit 
synthetic drug [1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP)]. In parallel, Langston et al. 
(1983) reported marked parkinsonism in four persons after using this drug intravenously. It was 
observed that this drug damaged the aminergic neurons of the substantia nigra.
Following this discovery, numerous studies based on the MPTP primate model were published 
over the last 25 years using various administration regimens. However, this model is not without 
limitations as indicated by Fox and Brotchie (2010) (a reference cited by the authors), who write that 
“Despite these obvious successes, limitations still exist in the model, particularly when consider-
ing underlying mechanisms of disease progression; thus, it appears difficult to reliably use acute 
toxin administration to replicate a chronic progressive disorder and provide consistent evidence 
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of Lewy-like bodies.” Indeed as indicated by Halliday et  al. 
(2009), inclusion of Lewy body-like formation is not prevalent 
in the MPTP monkey model. However, treatment of the NHP 
with l-DOPA induced involuntary movements resembling the 
phenomenology of human dyskinesias (Johnston and Fox, 2015).
Furthermore, long before the MPTP model existed, basic con-
cepts of deep-brain stimulation had been developed in the 1960s. 
Jasper (1966) used microelectrodes to record electrical activity 
from single nerve fibers in the thalamus of patients with PD and 
showed that stimulation of the junction of the ventralis lateralis 
and the ventralis posterior nuclei of the thalamus stopped their 
tremor. Early surgical interventions for PD in human patients 
were attempted throughout the twentieth century by perform-
ing extirpations, clipping or lesions in multiple locations from 
the cortex to the spinal cord. Later, the number of surgeries 
decreased after l-DOPA became available at the end of the 60s. 
This number started to increase again after the presence of severe 
side effects associated with l-DOPA administration was reported. 
However, the proposed surgeries used reversible chronic electri-
cal stimulation of various brain nuclei. Benabid et  al. (1987) 
reported tremor reduction using deep-brain stimulation of the 
ventrointermediate nucleus of the thalamus in patients with PD. 
This report was preceded by the work of Bechtereva et al. (1975), 
and thus several years before the first MPTP study.
More recently, Drouot et al. (2004) observed clinical improve-
ments in akinesia and bradykinesia following electrical stimula-
tion of the motor cortex of baboons, along with a normalization of 
firing rates and synchronization in the subthalamic nucleus and 
internal globus pallidus. The following clinical trial in patients 
with PD (http://clinicaltrials.gov/show/NCT00159172) did not 
demonstrate similar improvements and was interrupted. So, it is 
not clear to us what the authors are referring to when they refer 
to a “renaissance of Parkinson’s disease research.”
Computational (in  silico) models can contribute to explore 
the effects of DBS in PD, and there are today four main mod-
eling approaches including single-compartment spiking neuron 
models, phase oscillator models, multicompartmental spiking 
neuron models, and more recently, neural field models. Each 
type of model has its own assumptions, strengths, limitations, 
and advocates (for details, see Modolo et al., 2010). In the human 
brain, compensatory mechanisms and plasticity are fundamental 
issues and biologically realistic models associated with clinical 
studies conducted in human subjects by design integrate these 
issues. In any case, computational or NHP models should be 
subjected to an ethical review process before their application to 
human patients can be considered.
Today DBS research is moving toward closed loop control of 
disease based on real-time adaptive (intelligent) brain stimulators 
(Little et al., 2013; McIntyre et al., 2015) using biomarkers, such as 
local-field potentials. These new approaches are tested in human 
subjects because there is no alternative able to adapt to the chang-
ing behavior of each patient’s brain over time as well as to the 
evolution of the disease. It should be noted that the novel methods 
discussed here refer specifically to brain neuromodulation and do 
not cover disease-modifying treatments, such as drugs, stem cells, 
and antibodies. Hence, we agree with the concluding remark of 
the authors (cited above) but the arguments they develop appear 
somewhat contradictory to their conclusion. As a result, based 
on historical data and recent developments in the field, we do 
not support the hypothesis that NHPs constitute a valid scientific 
modality for the complete understanding of PD and for the 
development of future neuromodulation therapeutic strategies.
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